Skip to main content
Premium Trial:

Request an Annual Quote

Illumina to Offer $325M in Convertible Notes; Will Use $200M to Repurchase Shares

NEW YORK (GenomeWeb News) - Illumina plans to sell $325 million in convertible senior notes pay for corporate expenses, the company said today.
 
Illumina said it will use roughly $200 million of the proceeds to buy shares of its common stock in a private transaction, and some of the rest will go to pay the cost of the convertible transactions.
 
The notes will be due 2014 and upon conversion holders will receive cash value for the principal amount and any excess will be given in common stock.
 
Any remaining balance will go to general corporate purposes, which the company said could include acquisitions or more purchases of its own stock.
 
Illumina said the interest rate and other terms have yet to be negotiated.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.